CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Targeting BCMA in Multiple Myeloma.
Targeting BCMA in Multiple Myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
综述目的：尽管过去十年多发性骨髓瘤（MM）治疗取得显著进展，仍有相当数量患者会对现有疗法产生进展。本综述回顾靶向B细胞成熟抗原（BCMA）的MM治疗方式，特别是抗体药物偶联物（ADC）、双特异性抗体构建体及嵌合抗原受体（CAR）修饰T细胞疗法，并概述已有临床数据报告或发表的各类疗法，以及这些新型药物的耐药机制。近期进展：目前正在开展多项临床试验，评估不同BCMA靶向方式治疗MM，结果显示前景良好。复发/难治性MM中，抗BCMA ADC和双特异性抗体构建体显示出显著疗效，且副作用可控。与此同时，过继细胞治疗使多次复发、难治性骨髓瘤患者获得显著且持久的应答。靶向BCMA的治疗策略在MM管理中潜力巨大，近期有望与现有标准疗法联合，以改善患者结局。此外，研究者正在评估克服抗BCMA治疗耐药机制的新方法。
PURPOSE OF REVIEW: Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a significant number of patients still progress on current available therapies.
Here, we review treatment modalities used to target BCMA in the treatment of MM, specifically antibody-drug conjugates (ADC), bispecific antibody constructs, and chimeric antibody receptor (CAR) modified T-cell therapies.
We will provide an overview of therapies from these classes that have presented or published clinical data, as well as data on mechanisms of resistance to these novel agents. RECENT FINDINGS: Clinical trials exploring different BCMA-targeting modalities to treat multiple myeloma are underway and demonstrate promising results. In relapsed/refractory multiple myeloma, anti-BCMA ADCs and bispecific antibody constructs are showing impressive efficacy with manageable side effect profiles.
In parallel, adoptive cellular therapy has induced dramatic durable responses in multiply relapsed and refractory myeloma patients. Therapeutic approaches targeting BCMA hold significant potential in the management of multiple myeloma and will soon be incorporated in combination with current standard therapies to improve outcomes for patients with multiple myeloma.
In addition, novel approaches are being evaluated to overcome resistance mechanisms to anti-BCMA therapies.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
